The HIV Game-Changer You NEED to Know About: Lenacapavir Unveiled!
By Fellow NursesAfrica| September 28, 2025
As nurses, you are pivotal in combating HIV/AIDS, a crisis that continues to challenge global health, particularly in sub-Saharan Africa, where 67% of the world’s 38 million HIV cases reside. Enter lenacapavir, a revolutionary long-acting antiretroviral from Gilead Sciences that’s transforming HIV prevention and treatment. Often mistaken for an “HIV vaccine” due to its near-perfect efficacy, lenacapavir is not a vaccine but a capsid inhibitor with unprecedented potential. This article by Fellow Nurses Africa, unveils lenacapavir’s mechanism, evidence, and nursing implications, offering an eye-opening look at a tool that could redefine HIV care.
Lenacapavir: Not a Vaccine, but a Breakthrough
Lenacapavir is not a vaccine that confers immunity but a first-in-class capsid inhibitor that disrupts HIV-1 replication by targeting its protein shell, preventing viral entry and assembly. Unlike daily oral regimens, it’s administered as subcutaneous injections every six months, marketed as Sunlenca for treatment and Yeztugo for pre-exposure prophylaxis (PrEP). This long-acting approach tackles adherence barriers like stigma and access, critical in high-burden regions.
Why It Matters for Nurses
Lenacapavir’s twice-yearly dosing empowers nurses to enhance patient care by simplifying regimens, reducing clinic visits, and addressing social challenges like stigma, particularly for women and key populations.
Lenacapavir in HIV Treatment
How It Works
Approved in 2022 for multidrug-resistant HIV-1, lenacapavir (Sunlenca) is used with other antiretrovirals for patients with limited options due to resistance or intolerance. It starts with oral loading (600 mg on days 1 and 2) and injections (927 mg on day 1), followed by maintenance doses every six months.
Evidence
The CAPELLA trial showed 83% of 72 heavily treatment-experienced patients achieved undetectable viral loads by week 52. Studies are exploring its use in treatment-naive patients and combinations like lenacapavir + bictegravir.
Nursing Role
- Administration: Master subcutaneous injection techniques for abdomen or thigh delivery.
- Counseling: Educate on combination therapy to prevent resistance and manage injection site reactions (69-83% of users, mostly mild).
- Monitoring: Track viral loads and adherence to dosing schedules.
Lenacapavir in HIV Prevention (PrEP)
How It Works
Approved as Yeztugo in June 2025 (FDA) and August 2025 (EU), lenacapavir is indicated for high-risk individuals (≥35 kg), including men who have sex with men, sex workers, and those with recent STIs. Dosing mirrors treatment, with oral bridging (300 mg weekly) if injections are delayed >14 days.
Evidence
- PURPOSE 1: 100% efficacy in preventing HIV among 2,134 cisgender women vs. background rates or daily PrEP.
- PURPOSE 2: 96% efficacy in 3,273 participants (mostly men, transgender, nonbinary), 89% better than daily PrEP. Overall, >99% efficacy across groups.
This is transformative for women, who represent 60% of new infections in Africa, offering discreet protection.
Nursing Role
- Screening: Confirm negative HIV status before starting and every six months, plus STI/hepatitis checks.
- Counseling: Clarify lenacapavir isn’t a vaccine, emphasize comprehensive prevention (e.g., condoms), and discuss pregnancy use with shared decision-making.
- Outreach: Build trust in communities to address stigma.
Safety Profile
Lenacapavir is well-tolerated, with injection site reactions (pain, nodules) in 69-83% of users, typically mild and rarely leading to discontinuation (0.2-1.2%). Nausea or gastrointestinal issues are less common, and no major drug interactions exist. Nurses must ensure no acute HIV infection before PrEP initiation to avoid resistance.
Access in Africa
Gilead is supplying lenacapavir at no profit in 120 high-burden countries, with generics costing ~$40/year per patient via partnerships with Unitaid, PEPFAR, and others. Supplies arrive by late 2025, with generics scaling up in 2026. Nurses should advocate for cold-chain infrastructure (lenacapavir requires refrigeration) and equitable distribution to rural and key populations.
Why Lenacapavir Is a Game-Changer
Lenacapavir’s >99% efficacy and long-acting dosing could slash new HIV infections and improve treatment outcomes, advancing UNAIDS 95-95-95 goals. Its discreet administration empowers women and key populations, while future research explores simpler regimens, like antibody combinations.
Call to Action for Nurses
Nurses are key to lenacapavir’s success:
- Train: Learn injection techniques, storage, and monitoring protocols.
- Educate: Debunk “vaccine” myths and promote lenacapavir’s role.
- Advocate: Push for equitable access in national HIV programs.
- Empower: Support patients with stigma-free, culturally sensitive care.
Lenacapavir is a beacon of hope. Seize this opportunity to lead the charge toward an AIDS-free future.
🚨 Stay Ahead in Nursing! 🚨 Be the first to see breaking nursing news, access career support, and unlock exclusive opportunities.
Resources: Visit Gilead’s access page or WHO HIV guidelines.
Fellow Nurses Africa is the independent voice of African nursing, we educate, inform and support nurses across Africa
Kehinde Oluwatosin is one of the many editors here at Fellow Nurses Africa and fellownurses.com.
He is a registered nurse with a Master of Science degree in healthcare leadership from the University of Hull, United Kingdom. Kehinde is passionate about advancing the nursing profession across Africa. As Co-Founder of Fellow Nurses Africa, he plays a key role in shaping editorial direction, ensuring our content educates, informs, and empowers nurses continent-wide.
With expertise in leadership, patient flow, and healthcare operations, Kehinde brings valuable insights to nursing news, career development, and policy discussions. He is committed to amplifying the voice of African nurses and driving positive change in the profession.
